Candriam SCA’s GenMark Diagnostics, Inc GNMK Stock Holding History

Candriam SCA’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-45,000	Closed	-$349K	–	662
2015 Q4	$349K	Hold	45,000	–	–	0.01%	499
2015 Q3	$354K	Hold	45,000	–	–	0.01%	564
2015 Q2	$408K	Hold	45,000	–	–	0.01%	556
2015 Q1	$584K	Sell	45,000 -10,000	-18%	-$131K	0.01%	527
2014 Q4	$749K	Buy	+55,000	New	+$615K	0.02%	467

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Candriam SCA's GNMK Position: Q1 2016 in Review

Candriam SCA sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2016, closing a stake of 45,000 shares — an estimated $349K sold.

Candriam SCA first reported a position in GNMK in Q4 2014 and held it in 5 quarters. The position peaked at $749K in Q4 2014. 86 funds tracked by Wall St. Rank hold GNMK as of Q1 2016.

Candriam SCA reported no remaining GenMark Diagnostics, Inc position as of Q1 2016 after selling out during the quarter.
Candriam SCA sold 45,000 GenMark Diagnostics, Inc shares in Q1 2016, an estimated $349K.
Candriam SCA first reported a position in GenMark Diagnostics, Inc in Q4 2014 and held it in 5 quarters.
Candriam SCA's GenMark Diagnostics, Inc position peaked at $749K in Q4 2014.
86 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2016.

Based on Candriam SCA's 13F filing for Q1 2016, filed 27 Apr 2016.